Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 849-864

  Maxwell, Steve A ^a,b   Cherry, Evan M ^a   Bayless, Kayla J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

14 3 3zeta ( ); Akt; B cell lymphoma; DLBCL; drug resistance; invasion; vimentin

Indexed keywords

CHAPERONE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENOLASE; ENOLASE 1; EZRIN; GLYCINE HYDROXYMETHYLTRANSFERASE; PREDNISONE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; SMALL INTERFERING RNA; SORCIN; STRATIFIN; TRIOSEPHOSPHATE ISOMERASE; TRIOSEPHOSPHATE ISOMERASE 1; TUBULIN SPECIFIC CHAPERONE B; UNCLASSIFIED DRUG; VIMENTIN; VINCRISTINE; WITHAFERIN A;

ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

14-3-3 PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM INVASIVENESS; PREDNISONE; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VIMENTIN; VINCRISTINE;

EID: 79955070726     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.551793     Document Type: Article

References (87)

1. Ng AK. Diffuse large B cell lymphoma. Semin Radiat Oncol 2007;17:169-75.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
3. Czuczman MS, Rummel MJ. Recent advances in NHL. Clin Adv Hematol Oncol 2010;9:2-11.
4. Woolley PV, Osborne CK, Levi JA, Wiernik PH, Canellos GP. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976;38:1026-35.
5. Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Immunol 1999;63:180-191. (Pubitemid 29406735)
6. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990;82:501-509. (Pubitemid 20108054)
7. Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, al-Katib A. A human B-cell lymphoma line with a de novo multidrug resistance phenotype. Cancer 1992;69:1468-1474.
8. Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284:22379-22389.
9. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127. (Pubitemid 46638950)
10. Blomgren, H, Hallstrom M. Possible role of acrolein in 4-hydroperoxycyclophosphamide-induced cell damage in vitro. Methods Find Exp Clin Pharmacol 1991;13:11-14.
11. Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 1998;213:157-167. (Pubitemid 28332808)
12. Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 1994;170:211-224. (Pubitemid 24122510)
13. Su SC, Mendoza EA, Kwak HI, Bayless KJ. Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in would healing. Am J Physiol Cell Physiol 2008;295:C1215-C1229. (Pubitemid 352790352)
14. Fisher KE, Pop A, Koh W, Anthis NJ, Saunders WB, Davis GE. Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol Cancer 2006;5:69.
15. Bayless KJ, Kwak HI, Su SC. Investigating endothelial invasion and sprouting behavior in three-dimensional collagen matrices. Nat Protoc 2009;4:1888-1898.
16. Clarke L, Waxman DJ. Oxidative metabolism of cyclopho-sphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989;49:2344-2350. (Pubitemid 19125559)
17. Murray GI, Taylor MC, McFadyen MC, et al. Tumour-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-3031. (Pubitemid 27315056)
18. Islam TC, Lindvall J, Wennborg A, Brandén LJ, Rabbani H, Smith CI. Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays. Eur J Immunol 2002;32:982-993. (Pubitemid 34428813)
19. Podolin PL, Prystowsky MB. The kinetics of vimentin RNA and protein expression in interleukin 2-stimulated T lymphocytes. J Biol Chem 1991;266:5870-5875.
20. Smith PG, Wang F, Wilkinson KN, et al. The phosphodies-terase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005;105: 308-316. (Pubitemid 40053098)
21. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidy-linositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186. (Pubitemid 44913290)
22. Faber AC, Dufort FJ, Blair D, Wagner D, Roberts MF, Chiles TC. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 2006;72:1246-1256. (Pubitemid 44572191)
23. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 2008;17:159-165.
24. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009;114:2926-2935.
25. Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010;149: 560-568.
26. Lertprasertsuke N, Tsutsumi Y, Maruyama T. B-cell lymphoma with vimentin-positive cytoplasmic inclusions. Acta Pathol Jpn 1991;41:473-479.
27. Sarker AB, Akagi T, Yoshino T, Hoshida Y, Takahashi K, Horie Y. Expression of vimentin and epithelial membrane antigen in human malignant lymphomas. Acta Pathol Jpn 1990;40:581-587. (Pubitemid 20328976)
28. Gustmann C, Altmannsberger M, Osborn M, Griesser H, Feller AC. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas. Am J Pathol 1991;138:1413-1422.
29. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385: 399-408. (Pubitemid 40165072)
30. Eriksson JE, Dechat T, Grin B, et al. Introducing intermediate filaments: from discovery to disease. J Clin Invest 2009;119: 1763-1771.
31. Mendez MG, Kojima SI, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010;24:1838-1851.
32. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
33. Bargagna-Mohan P, Hamza A, Kim YE, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 2007;14: 623-634. (Pubitemid 46920982)
34. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8: 27-36. (Pubitemid 351237907)
35. Chatterjee D, Goldman M, Braastad CD, et al. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int J Oncol 2004;25:503-509.
36. Neal CL, Yao J, Yang W, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69:3425-3432.
37. Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 2008;105: 162-167.
38. Powell DW, Rane MJ, Chen Q, Singh S, McLeish KR. Identification of 14-3-3zeta as a protein kinase B/Akt substrate. J Biol Chem 2002;277:21639- 21642. (Pubitemid 34952313)
39. Obsil T, Ghirlando R, Anderson DE, Hickman AB, Dyda F. Two 14-3-3 binding motifs are required for stable association of Forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding. Biochemistry 2003;42:15264-15272. (Pubitemid 38031725)
40. Yang H, Masters SC, Wang H, Fu H. The proapoptotic protein Bad binds the amphipathic groove of 14-3-3zeta. Biochim Biophys Acta 2001;1547:313-319. (Pubitemid 32532149)
41. Singh LP, Jiang Y, Cheng DW. Proteomic identification of 14-3-3zeta as an adapter for IGF-1 and Akt/GSK-3beta signaling and survival of renal mesangial cells. Int J Biol Sci 2006;3:27-39. (Pubitemid 46155760)
42. Zhou J, Shao Z, Kerkela R, et al. Serine 58 of 14-3-3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol 2009;29:4167-4176.
43. DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005;4: 271-279. (Pubitemid 40340206)
44. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7:e17.
45. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-24. (Pubitemid 40444644)
46. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007;25:917-931. (Pubitemid 46436532)
47. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010;2:19-42.
48. Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008;27:1932-1943.
49. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3'-kinase/AKT pathways. Oncogene 2005;24:7443-7454. (Pubitemid 41637984)
50. Fortier A-M, Themsche CV, Asselin E, Cadrin M. Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett 2010;584:984-988.
51. Tavassoli M, Hardy C. Molecular basis of homing of intra-venously transplanted stem cells to the marrow. Blood 1990;76:1059-1070. (Pubitemid 20318147)
52. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76: 301-314. (Pubitemid 24046692)
53. Nieminen M, Henttinen T, Merinen M, Marttila-Ichihara F, Eriksson JE, Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 2006;8: 156-162.
54. Rafa L, Dessein AF, Devisme L, et al. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010;36:689-698.
55. Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol 2010;36:181-192.
56. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 2009;100:1834-1841.
57. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007;67:1979-1987. (Pubitemid 46424214)
58. Kumar S, Bryant CS, Chamala S, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 2009;8:26.
59. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422. (Pubitemid 46218735)
60. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926-7935. (Pubitemid 37466729)
61. Hutcheson IR, Knowlden JM, Hiscox SE, et al. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 2007;9:R50.
62. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M. Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ 2009;16: 571-583.
63. Li L, Wei XH, Pan YP, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010;29: 5785-5795.
64. Zhu QS, Rosenblatt K, Huang KL, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2010 Sep 20. [Epub ahead of print].
65. Lahat G, Zhu QS, Huang KL, et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010;5:e10105.
66. Zhang MH, Lee JS, Kim HJ, et al. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. Mol Cell Biochem 2006;281:111-121.
67. Yang X, Wang J, Liu C, et al. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol 2005;167:705-719. (Pubitemid 41216356)
68. Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22: 1755-1766.
69. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-1399. (Pubitemid 41129606)
70. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-1384. (Pubitemid 41348658)
71. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. (Pubitemid 36857789)
72. Amini RM, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 2002;43:2179-2189. (Pubitemid 35189521)
73. Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005;68: 422-431. (Pubitemid 41160973)
74. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-3313.
75. Al-Katib AM, Smith MR, Kamanda WS, et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998;4:1305-1314. (Pubitemid 28213344)
76. Tsukita S, Yonemura S. Cortical actin organization: Lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 1999;274:34507-34510. (Pubitemid 129509480)
77. Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 2004;112:165-176. (Pubitemid 38703562)
78. Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study. Proteomics 2006;6:1681-1694.
79. 2+-binding proteins. Biochim Biophys Acta 2002;1600:51-60. (Pubitemid 38224398)
80. Yang YX, Chen ZC, Zhang GY, Yi H, Xiao ZQ. A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem 2008;104:1010-1021. (Pubitemid 351830847)
81. Qi J, Liu N, Zhou Y, et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 2006;349:303-309. (Pubitemid 44348892)
82. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166-2170. (Pubitemid 17102655)
83. Bruno NA, Slate DL. Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J Natl Cancer Inst 1990;82:419-424. (Pubitemid 20108035)
84. Liu Y, Liu H, Han B, Zhang JT. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006;66: 3248-3255.
85. Li Y, Chen HQ, Chen MF, et al. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Sci 2009;84:882-887.
86. Selga E, Morales C, Noé V, Peinado MA, Ciudad CJ. Role of caveolin 1, E-cadherin, enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 2008;1:35.
87. Johnsson A, Zeelenberg I, Min Y, et al. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 2000;83:1047-1054.